(APASL) 23rd Conference of the Asian Pacific Association for the Study of the Liver, 6-9 June, 2013, Singapore

Conference Reports for NATAP


(APASL) 23rd Conference of the Asian Pacific Association for the Study of the Liver 6-9 June, 2013, Singapore

	Hepatitis B Virus Infection in Western Region of China - (07/01/13) Vaniprevir (MK-7009) in Treatment-Experienced Genotype (GT) 1 HCV-Infected Patients Demonstrates Time-Dependent Pharmacokinetics (PK) - (06/27/13) SVR Reduces HCC, decompensated cirrhosis, transplant, death by 50% & more: Projected Long-Term Impact of Vaniprevir (MK-7009) for Previously Treated Chronic HCV Genotype 1 Infection - (06/27/13) Hepatitis C Virus Infection in Western Region of China - (06/27/13) ELECTRON: All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic HCV GT 1 Infection - (06/25/13) Treatment with Sofosbuvir+Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: The POSITRON Trial - (06/25/13) All-Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial - (06/25/13) Interim analysis of An INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN of DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS - (06/25/13) Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (06/25/13) ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C - (06/23/13) VX-135 FOR THE TREATMENT OF CHRONIC HEPATITIS - In Vitro Safety/Potency/Mechanism - (06/23/13) Boehringer Ingelheim's investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients - press release, link to presentation - (06/23/13) Boehringer Ingelheim's investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia - press release, link to presentation - (06/23/13) Up to 91% SVR rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a (40KD)/ribavirin (P/R) in HCV genotype (G)1b-infected prior partial/null responders - (06/20/13) Low rate of danoprevir resistance with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV G1b-infected treatment-naive and treatment-experienced patients - (06/20/13) High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3 (updated SVR12 reported, previously at AASLD/2012 SVR4 was reported for 12-week regimen) - (06/20/13) No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/19/13) Six Years of Treatment With Tenofovir DF for Chronic Hepatitis B Virus Infection is Safe and Well Tolerated and Associated With Sustained Virological, Biochemical, and Serological Responses With No Detectable Resistance - (06/19/13) 48 Weeks TDF Treatment Results in Potent Viral Suppression and A Favorable Safety Profile in Chinese Chronic Hepatitis B Patients - (06/19/13) Tenofovir Disoproxil Fumarate (TDF) in Asian Patients With High Baseline HBV-DNA Viral Load (HBV DNA ≥9 log10 copies/mL) - (06/19/13) High Prevalence of Vitamin D Deficiency Among Chronic Hepatitis B Patients Entering a Large Global Prospective Trial (Study GS-US-174-0149) - (06/19/13) Chronic Hepatitis B Treatment With Tenofovir DF (TDF): 2-Year Efficacy and Safety Results in a Real-Life Cohort - (06/19/13) Regression of Cirrhosis After HBsAg Seroconversion in a Cirrhotic 38 Year-Old Bangladeshi Man Treated with Tenofovir Disoproxil Fumarate - (06/19/13) HBsAg level predicts sustained response in peginterferon alfa-2a (40KD)-treated HBeAg-positive patients: initial post-treatment results from the 'real-life' S-Collate cohort - (06/17/13) Early on-treatment HBsAg level predicts response in HBeAg-positive chronic hepatitis B patients switched from long-term entecavir to peginterferon alfa-2a (40KD) - (06/17/13) The Relative Disease Burden of Viral Hepatitis C: A Comparison with Viral Hepatitis B - (06/17/13) Reasons for Treatment Discontinuation Among Hepatitis C Patients Treated in Clinical Practice - (06/17/13) N-CORE: sustained virological response rates with peginterferon alfa-2a/ribavirin (PegIFN alfa 2a/RBV) in HCV G2 or 3 patients without rapid virological response - (06/17/13) Baseline viral load thresholds predicting virological response to peginterferon alfa-2a/ribavirin in HCV G2 and G3 patients: PROPHESYS cohort sub-analysis - (06/17/13) Peginterferon Lambda for the Treatment of HBeAg-Positive Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa - (06/14/13) Interim analysis of An INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN of DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS - (06/14/13) Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor[protease]) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV)....and triple all-oral Daclatasvir+Asunaprevir+Rbv (gt1a/1b) - (06/14/13) Peginterferon Lambda-1a (Lambda) is Associated With Less Autoimmune Thyroid Disease and Serious Autoimmune Disease Than Peginterferon Alfa-2a (Alfa) When Used in Combination With Ribavirin (RBV) for the Treatment of Chronic Hepatitis C Virus Infection - (06/14/13) No Detectable Tenofovir Resistance With Tenofovir Disoproxil Fumarate (TDF) or TDF+Emtricitabine (FTC/TDF) Through 96 Weeks in Lamivudine-Resistant CHB Patients - (06/12/13) Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients With Documented Lamivudine Resistance (LAM-R) - (06/12/13) Robust and Persistent Replication of Genotype 6a Hepatitis C Virus Replicon in Cell Culture - (06/12/13) INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR (BI 207127) AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV-GT1B - (06/10/13) HCV in China....Extrahepatic Diseases HCV R.E.V.E.A.L. Study in Taiwan - (06/10/13) No Ethnic Differences in the Pharmacokinetics of Sofosbuvir or Sofosbuvir/Ledipasvir Fixed Dose Combination in Japanese and Caucasian Subjects - (06/10/13) Hepatitis C Disease Awareness and Access to Care in India: a Multicenter, National Survey - (06/09/13) High SVR24 rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV genotype (G)1/4-infected treatment-naive patients: the DAUPHINE study - (06/09/13) FALDAPREVIR PLUS PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAïVE PATIENTS: SUBANALYSIS OF PATIENTS FROM JAPAN, TAIWAN AND SOUTH KOREA - (06/09/13) Ritonavir boosting of the HCV protease inhibitor danoprevir (DNVr) significantly reduces reactive metabolite formation in vitro and in vivo - (06/09/13) A 12-Week Trial of Interferon-free Regimens Containing ABT-450/r and ABT-267 ± Ribavirin (RBV) in Treatment-naïve Patients With HCV Genotypes 1-3 - (06/09/13) INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN ACHIEVE HIGH SVR12 AND SVR24 RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1b - (06/09/13)